E-cadherin and cytokeratin subtype profiling in effusion cytology

Journal of Korean Medical Science

Volumn 19, Issue 6, 2004, Pages 826-833

  Han, Joungho ^a   Kim, Mi Kyung ^a   Nam, Seok Jin ^a   Yang, Jung Hyun ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Ascites; Cadherins; Carcinoma; Cytokeratin 20; Keratin; Keratin 7; Mesothelioma; Neoplasms, Mesothelial; Pleural Effusion

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN; CYTOKERATIN 17; CYTOKERATIN 20; CYTOKERATIN 5; CYTOKERATIN 6; EPITHELIAL MEMBRANE ANTIGEN; UVOMORULIN;

ARTICLE; COLON CARCINOMA; CONTROLLED STUDY; CYTOLOGY; CYTOPATHOLOGY; GASTROINTESTINAL CARCINOMA; GASTROINTESTINAL TRACT; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERPLASIA; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; MESOTHELIOMA; MESOTHELIUM; METASTASIS; MOLECULAR WEIGHT; MUCINOUS CARCINOMA; NEOPLASM; OVARY CARCINOMA; PROTEIN EXPRESSION; RECTUM CARCINOMA;

EID: 12144265009     PISSN: 10118934     EISSN: None     Source Type: Journal    
DOI: 10.3346/jkms.2004.19.6.826     Document Type: Article

References (34)

1. Peralta Soler A, Knudsen KA, Jaurand MC, Johnson KR, Wheelock MJ, Klein-Szanto AJ, Salazar H. The differential expression of N-cadherin and E-cadherin distinguishes pleural mesotheliomas from lung adenocarcinomas. Hum Pathol 1995; 26: 1363-9.
2. Leers MP, Aarts MM, Theunissen PH. E-cadherin and calretinin: a useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma. Histopathology 1998; 32: 209-16.
3. Lim SJ, Kim GY, Kim YW, Park YK, Lee J, Yang MH, Won NH. Usefulness of E-cadherin expression in malignant effusion. Korean J Cytopathol 1999; 10: 121-6.
4. Ordonez NG. Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma. Am J Surg Pathol 1998; 22: 1215-21.
5. Ordonez NG. Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma. Am J Surg Pathol 2000; 24: 598-606.
6. Kim BH, Kwon OJ. Immunocytochemical expression of E-cadherin in cell blocks of serous effusions. Korean J Cytopathol 2001; 12: 81-8.
7. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science 1991; 251: 1451-5.
8. Shimoyama Y, Hirohashi S, Hirano S, Noguchi M, Shimosato Y, Takeichi M, Abe O. Cadherin cell-adhesion molecules in human epithelial tissues and carcinomas. Cancer Res 1989; 49: 2128-33.
9. Peralta Soler A, Knudsen KA, Tecson-Miguel A, McBrearty FX, Han AC, Salazar H. Expression of E-cadherin and N-cadherin in surface epithelial-stromal tumors of the ovary distinguishes mucinous from serous and endometrioid tumors. Hum Pathol 1997; 28: 734-9.
10. Simsir A, Fetsch P, Mehta D, Zakowski M, Abati A. E-cadherin, N-cadherin, and calretinin in pleural effusions: the good, the bad, the worthless. Diagn Cytopathol 1999; 20: 125-30.
11. Cooper D, Schermer A, Sun TT. Classification of human epithelia and their neoplasms using monoclonal antibodies to keratins: strategies, applications, and limitations. Lab Invest 1985; 52: 243-56.
12. Battifora H. Pleura. In: Sternberg SS eds. Diagnostic Surgical Pathology, 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 1999: 1117-45.
13. Clover J, Oates J, Edwards C. Anti-cytokeratin 5/6: a positive marker for epithelioid mesothelioma. Histopathology 1997; 31: 140-3.
14. O'Malley FP, Grignon DJ, Shum DT. Usefulness of immunoperoxidase staining with high-molecular-weight cytokeratin in the differential diagnosis of small-acinar lesions of the prostate gland. Virchow Arch A Pathol Anat Histopathol 1990; 417: 191-6.
15. Wojno KJ, Epstein JI. The utility of basal cell-specific anti-cytokeratin antibody (34bE12) in the diagnosis of prostate cancer. A review of 228 cases. Am J Surg Pathol 1995; 19: 251-60.
16. Moinfar F, Man YG, Lininger RA, Bodian C, Tavassoli FA. Use of keratin 34betaE12 as an adjunct in the diagnosis of mammary intraepithelial neoplasia-ductal type-benign and malignant intraductal proliferations. Am J Surg Pathol 1999; 23: 1048-58.
17. Miettinen M, Nobel MP, Tuma BT, Kovatich AJ. Keratin 17: Immunohistochemical mapping of its distribution in human epithelial tumors and its potential applications. Appl Immunohistochem 1997; 5: 152-9.
18. Ordonez NG. Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas. Am J Surg Pathol 1998; 22: 1203-14.
19. Shimoyama Y, Hirohashi S. Cadherin intercellular adhesion molecule in hepatocellular carcinomas: loss of E-cadherin expression in an undifferentiated carcinoma. Cancer Lett 1991; 57: 131-5.
20. Mayer B, Johnson JP, Leitl F, Jauch KW, Heiss MM, Schildberg FW, Birchmeier W, Funke I. E-cadherin expression in primary and metastatic gastric cancer: down-regulation correlates with cellular dedifferentiation and glandular disintegration. Cancer Res 1993; 53: 1690-5.
21. Pignatelli M, Liu D, Nasim MM, Stamp GW, Hirano S, Takeichi M. Morphoregulatory activities of E-cadherin and beta-1 integrins in colorectal tumour cells. Br J Cancer 1992; 66: 629-34.
22. Hashimoto M, Niwa O, Nitta Y, Takeichi M, Yokoro K. Unstable expression of E-cadherin adhesion molecules in metastatic ovarian tumor cells. Jpn J Cancer Res 1989; 80: 459-63.
23. Bussemakers MJ, van Moorselaar RJ, Giroldi LA, Ichikawa T, Isaacs JT, Takeichi M, Debruyne FM, Schalken JA. Decreased expression of E-cadherin in the progression of rat prostatic cancer. Cancer Res 1992; 52: 2916-22.
24. Kinsella AR, Green B, Lepts GC, Hill CL, Bowie G, Taylor BA. The role of the cell-cell adhesion molecule E-cadherin in large bowel tumour cell invasion and metastasis. Br J Cancer 1993; 67: 904-9.
25. Ross JS, Figge HL, Bui HX, del Rosario AD, Fisher HA, Nazeer T, Jennings TA, Ingle R, Kim DN. E-cadherin expression in prostatic carcinoma biopsies: correlation with tumor grade, DNA content, pathologic stage, and Mod Pathol clinical outcome. Mod Pathol 1994; 7: 835-41.
26. Tsuji K, Hirano T, Shibanuma H, Okada S, Kawate N, Konaka C, Ebihara Y, Kato H. Cytologic features based on the expression of E-cadherin and catenins in lung adenocarcinoma. Acta Cytol 1999; 43: 381-9.
27. Frixen UH, Behrens J, Sachs M, Eberle G, Voss B, Warda A, Lochner D, Birchmeier W. E-cadherin mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 1991; 113: 173-85.
28. Ross JS, Cheung C, Sheehan C, del Rosario AD, Bui HX, Fisher HA. E-cadherin cell-adhesion molecule expression as a diagnostic adjunct in urothelial cytology. Diagn Cytopathol 1996; 14: 310-5.
29. Gamallo C, Palacios J, Suarez A, Pizarro A, Navarro P, Quintanilla M, Cano A. Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma. Am J Pathol 1993; 142: 987-93.
30. Taki A, Nakatani Y, Misugi K, Yao M, Nagashima Y. Chromophobe renal cell carcinoma: An immunohistochemical study of 21 Japanese cases. Mod Pathol 1999; 12: 310-7.
31. Chu P, Wu E, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: A survey of 435 cases. Mod Pathol 2000; 13: 962-72.
32. Wang NP, Zee S, Zarbo RJ, Bacchi CE, Gown AM. Coordinate expression of cytokeratins 7 and 20 defines unique subsets of carcinomas. Appl Immunohistochem 1995; 3: 99-107.
33. Ascoli V, Taccogna S, Scalzo CC, Nardi F. Utility of cytokeratin 20 in identifying the origin of metastatic carcinomas in effusions. Diagn Cytopathol 1995; 12: 303-8.
34. Miettinen M. Keratin 20: Immunohistochemical marker for gastrointestinal, urothelial, and Merkel cell carcinomas. Mod Pathol 1995; 8: 384-8.